Resumen de las cotizaciones máximas, mínimas y variaciones del Elicio Therapeutics
Precios históricos de las acciones
Precio actual de la acción	US$9.95
Máximo en las últimas 52 semanas	US$14.93
Mínimo de 52 semanas	US$5.24
Beta	1.45
Cambio en 1 mes	-16.94%
Variación en 3 meses	13.71%
Cambio de 1 año	75.80%
Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	-45.16%

Noticias y actualizaciones recientes

Actualización de narrativa • May 21

Favorable Auction Dynamics

While Merck and Amgen are the frontrunners for a KRAS-driven partnership, Elicio’s AMP platform is particularly attractive to a broader subset of "Big Pharma" companies that are currently facing a specific strategic gap: the inability of their existing portfolios to penetrate "cold" tumors like pancreatic (PDAC) and colorectal (CRC) cancers. It is most probable that big pharma is conducting due diligence into RVMD and ELTX in parallel and evaluating outcomes and potential synergies with their existing portfolios.

Actualización de narrativa • May 05

Valuation: 15x upside potential

Determining the valuation for Elicio Therapeutics (ELTX) requires balancing the high-cost nature of specialized immunotherapy with the massive patient populations affected by KRAS mutations. Based on current oncology benchmarks and the clinical profile of the AMP-7P vaccine, here is the projected economic outlook.

Actualización de narrativa • Apr 29

Study on track for success

As of April 28, 2026, based on the enrollment completion of the AMPLIFY-7P Phase 2 study in November 2024, approximately 40% to 45% of the MRD-negative cohort should have progressed by now if there were no treatment effect. This calculation is based on the clinical parameters and natural history data provided in the sources: 1.

Recent updates

Actualización de narrativa • May 21

Favorable Auction Dynamics

Actualización de narrativa • May 05

Valuation: 15x upside potential

Actualización de narrativa • Apr 29

Study on track for success

Actualización de narrativa • Feb 21

10 mg adjuvant = 100% mKRAS specific T-cell response rate

The 10 mg dose of Amph-CpG-7909 improves vaccine efficacy by providing an optimized level of Toll-like receptor 9 (TLR-9) stimulation that is precisely targeted to the lymph nodes, resulting in a 100% T cell response rate and significantly enhanced anti-tumor activity compared to lower doses. The specific mechanisms by which this dose and formulation improve efficacy include: 1.

Artículo de análisis • Feb 10

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Actualización de narrativa • Jan 18

80-90% prob of success

Assuming a conservative 16-month median Disease-Free Survival (DFS) for the observation group—consistent with a nationwide, unselected (MRD-agnostic) surgical PDAC population—the probability that the AMPLIFY-7P Phase 2 study will show a statistically significant improvement in the treatment arm is estimated to be 80–90%. While the 16-month baseline represents a significantly more durable control group than the 5.0–6.4 month median seen in MRD-positive patients, the following factors derived from the sources support this high estimate: 1.

Seeking Alpha • Nov 07

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Summary ELTX is continuing its work on a KRAS vaccine in PDAC, with a phase 2 trial set to read out any day now. Earlier signals of efficacy of their phase 2 trial have shown biological correlation that suggests activity, but we still need to see outcomes of treatment. The company is heavily reliant on a positive read out in order to raise funds for further development. The potential upside here outweighs the admittedly huge downside risk, though. Read the full article on Seeking Alpha

Artículo de análisis • Aug 30

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Rentabilidad de los accionistas

	ELTX	US Biotechs	Mercado US
7D	-6.4%	1.2%	1.0%
1Y	75.8%	34.9%	28.7%

Rentabilidad vs. Industria: ELTX superó a la industria US Biotechs, que obtuvo un rendimiento del 34.9% el año pasado.

Rentabilidad vs. Mercado: ELTX superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.

Volatilidad de los precios

Is ELTX's price volatile compared to industry and market?
ELTX volatility
ELTX Average Weekly Movement	13.1%
Biotechs Industry Average Movement	11.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de ELTX ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ELTX(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	33	Bob Connelly	elicio.com

Elicio Therapeutics, Inc, empresa de biotecnología en fase clínica, desarrolla inmunoterapias para el tratamiento del cáncer. Su principal producto candidato, ELI-002, es una vacuna péptida anfifílica (AMP) multivalente dirigida a ganglios linfáticos que se encuentra en ensayos clínicos de fase II para siete mutaciones conductoras del oncogén viral del sarcoma de rata de Kirsten. La empresa también desarrolla ELI-007, un tratamiento multivalente con péptidos AMP dirigido a los ganglios linfáticos para cánceres mutantes de sarcoma murino homólogo al oncogén viral B1-(BRAF), y ELI-008, una vacuna multivalente con péptidos AMP dirigida a los ganglios linfáticos que se encuentra en estudios preclínicos para el tratamiento de cánceres que expresan la proteína tumoral p53 mutada.

Resumen de fundamentos de Elicio Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Elicio Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de ELTX
Capitalización bursátil	US$182.12m
Beneficios(TTM)	-US$40.18m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-4.6x

Ratio precio-beneficio (PE)

¿Está ELTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ELTX
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$40.19m
Beneficios	-US$40.18m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.18
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	-659.4%

¿Cómo se ha desempeñado ELTX a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/22 12:07
Precio de las acciones al final del día	2026/05/22 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Elicio Therapeutics, Inc. está cubierta por 4 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Robert Burns	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Boris Peaker	JonesTrading Institutional Services, LLC

Elicio Therapeutics (ELTX) Resumen de Acciones

Análisis de riesgos

Top Community Narratives

Very Bullish

Top Community Narratives

Very Bullish

Competidores de Elicio Therapeutics, Inc.

Corbus Pharmaceuticals Holdings

Anika Therapeutics

Nkarta

Precision BioSciences

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

Recent updates

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

New minor risk - Share price stability

10 mg adjuvant = 100% mKRAS specific T-cell response rate

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

80-90% prob of success

Elicio Therapeutics, Inc. Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIF-7P Trial

Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Elicio Therapeutics, Inc. Announces Additional Immunogenicity Data from the Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P

Elicio Therapeutics, Inc. to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Elicio Therapeutics, Inc. Reports Robust T Cell Responses Across Diverse HLA Background in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics, Inc. Announces Investigator-Initiated Phase 1 Trial to Be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Elicio Therapeutics, Inc. Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-Up Data in Nature Medicine for Minimal Residual Disease Positive, Adjuvant-Stage Patients

New major risk - Revenue and earnings growth

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Growth Index

Elicio Therapeutics, Inc. announced that it expects to receive $10 million in funding

New major risk - Financial position

Elicio Therapeutics, Inc., Annual General Meeting, May 19, 2025

Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer

Director exercised options to buy US$28m worth of stock.

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000003 million.

New minor risk - Share price stability

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

New major risk - Financial position

Elicio Therapeutics, Inc. Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Elicio Therapeutics, Inc. Appoints Robert Connelly as Principal Accounting Officer and Principal Financial Officer

Price target decreased by 9.1% to US$10.00

Less than half of directors are independent

Elicio Therapeutics, Inc., Annual General Meeting, Nov 07, 2024

Elicio Therapeutics, Inc. announced that it expects to receive $20 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering.

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting

New major risk - Financial position

Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding from Gkcc, Llc

Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer

Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 At AACR Special Conference: Pancreatic Cancer

Less than half of directors are independent

Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Elicio Therapeutics, Inc.

Beneficios e Ingresos

Análisis de la empresa y estado de los datos financieros